Improved Long-Term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab

BACKGROUND & AIMS: Monitoring serum concentrations of tumor necrosis factor antagonists in patients receiving these drugs as treatment for inflammatory bowel disease (IBD), also called therapeutic drug monitoring, is performed either after patient loss of response (reactive drug monitoring) or i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Gastroenterol Hepatol
Egile Nagusiak: Papamichael, Konstantinos, Chachu, Karen A., Vajravelu, Ravy, Vaughn, Byron P., Ni, Josephine, Osterman, Mark T., Cheifetz, Adam S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5605429/
https://ncbi.nlm.nih.gov/pubmed/28365486
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cgh.2017.03.031
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak